Blog-Featured

Home Use of GENOSYL® Delivery System (DS) to Administer GENOSYL® (nitric oxide) gas for Inhalation for the Treatment of Pulmonary Hypertension Complicated by COVID-19 Infection Published in American Journal of Respiratory and Critical Care Medicine

Clinicians report on first at-home treatment of COVID-19 patient…
Blog-Featured

FDA Grants VERO Biotech Expanded Access Emergency Use for the Treatment of Patients with COVID-19, with the GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide

Blog-Featured

VERO Biotech Announces First Patient With COVID-19 Infection Complicating Pulmonary Hypertension Treated with GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide

Treatment informs FDA approval for emergency expanded access…
Blog-Featured

VERO Biotech, Leaders in the Development of Innovative Technologies for Inhaled Nitric Oxide Delivery, to Present at Biotech Showcase 2020

Prestigious investor conference runs concurrently with 38th Annual…
Blog-Featured

VERO Biotech Receives US FDA Approval of GENOSYL® for the Delivery of Inhaled Nitric Oxide

The GENOSYL® inhaled nitric oxide approval represents the…
Blog-Featured

AARC 2018

We will be attending the 2018 AARC Congress in Las Vegas on…
Blog-Featured

VERO Biotech Names Michael Gentile as Vice President of Medical Affairs

For Immediate Release Contact: Ray Russo (908) 313 -7172 Ray.Russo@VERO-biotech.com Atlanta-based…
Biotech-Firm-Opens-15,585-SF-Headquarters-at-Georgia-Tech’s-Technology-Enterprise-Park-in-Atlanta

Biotech Firm Opens 15,585 SF Headquarters at Georgia Tech’s Technology Enterprise Park in Atlanta

ATLANTA —VERO Biotech has opened a new 15,585-square-foot…
Blog-Featured

VERO Biotech Moves HQ to Atlanta

The biotechnology company left Florida for the Peach State, setting…